SCHEMBL1327017

SCHEMBL1327017

CCc1cccc(CC)c1-c1cc(Cl)c(C(=O)OC)c(C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
LMNA P02545 3/20 0.41
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 3/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1326971 0.91 SMN1; SMN2 (0.49) SMN1; SMN2LMNAPOLBKDM4EMEN1
SCHEMBL1327703 0.86 ALDH1A1 (0.39) SMN1; SMN2LMNAKDM4EGAAALDH1A1
SCHEMBL1328158 0.86 FABP4 (0.41) SMN1; SMN2LMNAKDM4EMEN1KMT2A
SCHEMBL1327125 0.86 C5AR1 (0.44) GAAALDH1A1C5AR1
SCHEMBL1328123 0.84 MRGPRX4 (0.39) SMN1; SMN2LMNAPOLBKDM4EMEN1
SCHEMBL1327487 0.83 CA12 (0.39) PLA2G2ASMN1; SMN2LMNAPOLBGAA
SCHEMBL1326963 0.80 C5AR1 (0.42) SMN1; SMN2KDM4EMEN1KMT2ANPC1
SCHEMBL1327094 0.78 SMN1; SMN2 (0.52) SMN1; SMN2LMNAPOLBKDM4EMEN1
SCHEMBL1327099 0.77 SMN1; SMN2 (0.51) SMN1; SMN2LMNAPOLBKDM4EMEN1
SCHEMBL17055115 0.77 SMN1; SMN2 (0.48) SMN1; SMN2LMNAPOLBKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565452-B1 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS NOVARTIS INT PHARM LTD (BM) 2012-04-04 EP disclosed
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed
EP-1565452-A2 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS NEUROGEN CORPORATION (US) 2005-08-24 EP disclosed
US-20040158067-A1 3-substituted-6-aryl pyridines NEUROGEN CORPORATION 2004-08-12 US disclosed
WO-2004043925-A2 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS NEUROGEN CORPORATION (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 PLA2G2A 477/4885SMN1; SMN2 4559/4885LMNA 3672/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 PLA2G2A 477/4885SMN1; SMN2 4559/4885LMNA 3672/4885
US-20040158067-A1 3-substituted-6-aryl pyridines C3AR1, C5AR1, C5AR2 PLA2G2A 448/4885SMN1; SMN2 4676/4885LMNA 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.